Strengths of our review are the systematic and broad search performed to include all possible studies, including those prior to peer‐review, to gather the largest number of studies available at this point. Exclusion of cases‐only studies, the largest number of the published cohorts of patients with COVID‐19, limits the available data but also improves the quality of the evidence and the possibility to present both sensitivity and specificity (cases only cannot provide both accuracy measures). Because this is a living systematic review, future updates may offer the possibility to do a meta‐analysis, which was not possible at this stage. In addition, further insights into this novel disease may lead to new evidence on signs and symptoms that are more diagnostic, which we will incorporate in future updates.